
Why Stop at HiSCR50?
Join Dr. Lima and Dr. Colantonio as they discuss the evolving treatment paradigm in hidradenitis suppurativa (HS). Through a review of current evidence and clinical experience, the session will examine the importance of striving for deeper disease control, intervening earlier in the disease course, and the potential role of bimekizumab in advancing the standard of care for patients with HS.
- Recognize the importance of aiming for a higher threshold of treatment success to ensure deeper disease control
- Understand the need for earlier and more effective treatment to prevent irreversible tissue and psychological damage
- Illustrate the role of bimekizumab in the pursuit of raising the standard of care in HS
